Therapeutic potential of vaccines in the management of hypertension

Drugs

Volumn 68, Issue 18, 2008, Pages 2557-2560

  Brown, Morris J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

CYT 006 AngQb, therapeutic use; Hypertension, treatment; Research and development; Vaccines, therapeutic use

Indexed keywords

ALDOSTERONE; ANGIOTENSIN I; ANGIOTENSIN II; CYT006 ANGQB VACCINE; KEYHOLE LIMPET HEMOCYANIN; PMD 3117; RENIN; UNCLASSIFIED DRUG;

ANTIBODY TITER; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; HUMAN; HYPERTENSION; IMMUNOGENICITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RNA PHAGE; VACCINATION; VIRUS PARTICLE;

ANIMALS; HUMANS; HYPERTENSION; OLIGOPEPTIDES; RENIN-ANGIOTENSIN SYSTEM; VACCINES; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 57749203373     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/0003495-200868180-00002     Document Type: Review

References (14)

1. Brown MJ. Renin: friend or foe? Heart 2007 Sep; 93 (9): 1026-33
2. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003 Nov 8; 362 (9395): 1527-35
3. National Institute for Clinical Excellence. CG34 hypertension: NICE guideline (all the recommendations) [online]. Available from URL: http://www.nice.org.uk/guidance/CG34/niceguidance/pdf/English [Accessed 2008 Oct 23]
4. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet 2005 Sep 10-16; 366 (9489): 895-906
5. Calhoun DA, Nishizaka MK, Zaman MA, et al. Hyperaldosteronism among Black and White subjects with resistant hypertension. Hypertension 2002 Dec 1; 40 (6): 892-6
6. Hood SJ, Taylor KP, Ashby MJ, et al. The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) double-blind cross-over trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. Circulation 2007 Jul 17; 116 (3): 268-75
7. Harrap SB, Van der Merwe WM, Griffin SA, et al. Brief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long-treatments term. Hypertension 1990 Dec; 16 (6): 603-14
8. Michel J-B. Renin-angiotensin vaccine: old story, new project 'efficacy versus safety'. Clin Sci 2004 Aug; 107 (2): 145-7
9. Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007 Jul 21; 370 (9583): 221-9
10. Brown MJ, Coltart J, Gunewardena K, et al. Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci (Lond) 2004 Aug; 107 (2): 167-73
11. Tissot AC, Maurer P, Nussberger J, et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 2008 Mar 8; 371 (9615): 821-7
12. Brown MJ. Aliskiren. Circulation 2008 Aug 12; 118 (7): 773-84
13. Ambuhl PM, Tissot AC, Fulurija A, et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 2007 Jan; 25 (1): 63-72
14. Gardiner SM, Auton TR, Downham MR, et al. Active immunization with angiotensin I peptide analogue vaccines selectively reduces the pressor effects of exogenous angiotensin I in conscious rats. Br J Pharmacol 2000 Mar; 129 (6): 1178-82